UCFA
ALNY icon

United Capital Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

United Capital Financial Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
4,155
+67
+2% +$20.2K 0.01% 728
2026
Q1 		$1.35M Buy
4,088
+1,639
+67% +$558K 0.01% 658
2025
Q4 		$974K Buy
2,449
+304
+14% +$135K 0.01% 741
2025
Q3 		$978K Buy
2,145
+570
+36% +$232K 0.01% 643
2025
Q2 		$514K Buy
1,575
+43
+3% +$11.9K ﹤0.01% 770
2025
Q1 		$414K Buy
1,532
+52
+4% +$13.4K ﹤0.01% 804
2024
Q4 		$348K Sell
1,480
-88
-6% -$23.1K ﹤0.01% 840
2024
Q3 		$431K Buy
1,568
+48
+3% +$12.5K ﹤0.01% 767
2024
Q2 		$369K Buy
+1,520
New +$240K ﹤0.01% 786
2021
Q3 		– Sell
-1,387
Closed -$235K – 1199
2021
Q2 		$235K Sell
1,387
-100
-7% -$14.6K ﹤0.01% 1102
2021
Q1 		$210K Sell
1,487
-1,669
-53% -$251K ﹤0.01% 1102
2020
Q4 		$410K Sell
3,156
-32,560
-91% -$4.35M ﹤0.01% 899
2020
Q3 		$5.2M Buy
35,716
+2,491
+7% +$354K 0.03% 337
2020
Q2 		$4.92M Buy
+33,225
New +$4.48M 0.04% 364
2016
Q4 		– Sell
-4,197
Closed -$284K – 1252
2016
Q3 		$284K Hold
4,197
– – ﹤0.01% 1092
2016
Q2 		$231K Sell
4,197
-53
-1% -$3.34K ﹤0.01% 1129
2016
Q1 		$267K Sell
4,250
-3
-0.1% -$199 ﹤0.01% 1032
2015
Q4 		$400K Hold
4,253
– – ﹤0.01% 939
2015
Q3 		$342K Sell
4,253
-86
-2% -$9.55K ﹤0.01% 1021
2015
Q2 		$520K Hold
4,339
– – 0.01% 904
2015
Q1 		$442K Buy
4,339
+765
+21% +$77.5K 0.01% 938
2014
Q4 		$347K Hold
3,574
– – 0.01% 927
2014
Q3 		$279K Buy
+3,574
New +$231K ﹤0.01% 951
2014
Q2 		– Sell
-3,500
Closed -$235K – 781
2014
Q1 		$235K Hold
3,500
– – 0.01% 840
2013
Q4 		$225K Hold
3,500
– – 0.01% 578
2013
Q3 		$224K Buy
+3,500
New +$174K 0.01% 611

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

United Capital Financial Advisors's ALNY Position: Q2 2026 in Review

United Capital Financial Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 1.6% in Q2 2026, buying an estimated $20.2K and bringing the position to 4,155 shares worth $1.25M. The position accounts for 0.01% of the portfolio, ranked #728.

United Capital Financial Advisors first reported a position in ALNY in Q3 2013 and has held it in 26 quarters since. The position peaked at $5.2M in Q3 2020. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • United Capital Financial Advisors held 4,155 shares of Alnylam Pharmaceuticals worth $1.25M as of Q2 2026.
  • United Capital Financial Advisors bought 67 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $20.2K.
  • Alnylam Pharmaceuticals made up 0.01% of United Capital Financial Advisors's portfolio in Q2 2026, its #728 holding.
  • United Capital Financial Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 26 quarters since.
  • United Capital Financial Advisors's Alnylam Pharmaceuticals position peaked at $5.2M in Q3 2020.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on United Capital Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.